Tokyo, Sept. 27 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063060) titled 'Development and Validation of a pT2N0-Exclusion Score to Aid Selection of Perioperative Chemotherapy (D-FLOT) Candidates in Gastric Cancer with Borderline Staging on Diagnostic Imaging' on Sept. 26.
Study Type:
Observational
Primary Sponsor:
Institute - Kameda Medical Center
Condition:
Condition - Gastric cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To develop and validate a statistical scoring system, based solely on preoperatively available information, for predicting the likelihood of pathological T2N0 gastric cancer, and to assess its discrimination, calibration, and clinical utility.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
=
Gender - Male and Female
Key inclusion criteria - Patients who underwent gastrectomy for gastric cancer at our department of gastroenterological surgery between April 1, 2000, and March 31, 2026, with pathological T factor of T2 or T3 and pathological N factor of N0 or N1.
Key exclusion criteria - Patients meeting any of the following criteria were excluded: (1) receipt of neoadjuvant chemotherapy; (2) positive peritoneal cytology or seeding; (3) distant metastasis (M1); (4) R2 resection; (5) special histological type, including neuroendocrine carcinoma.
Target Size - 469
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2026 Year 09 Month 17 Day
Date of IRB - 2026 Year 09 Month 17 Day
Anticipated trial start date - 2026 Year 09 Month 17 Day
Last follow-up date - 2026 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072190
Disclaimer: Curated by HT Syndication.
